ArticleFrontiers in cellular and infection microbiology2026
A novel SaeS-targeting antivirulence antagonist screened against methicillin-resistant
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The SaeRS two-component system is a major virulence regulator in Methods: In this study, we constructed a library of 1,093 compounds from PubChem and carried out structure-guided virtual screening against the SaeS kinase domain. This approach identified an amide-based candidate, designated Saeamid-1. Molecular docking and molecular dynamics simulations supported stable binding of Saeamid-1 within the nucleotide-binding region of SaeS, with a docking score of -9.884 kcal/mol. Results: The compound had only limited effects on bacterial growth. In contrast, it reduced hemolytic activity and biofilm biomass in USA300 by 65.74% and 88.77%, respectively. RT-qPCR analysis showed that Saeamid-1 reduced the expression of Conclusions: Taken together, these findings identify Saeamid-1 as a promising antivirulence candidate that targets SaeS in methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.